Anemia in Chronic Heart Failure

Tang, Yi-Da; Katz, Stuart D.

doi:10.1161/circulationaha.105.583666

Cited by 353 publications

(152 citation statements)

References 107 publications

(117 reference statements)

Supporting

Mentioning

143

Contrasting

Unclassified

Order By: Relevance

“…Anaemia is prevalent in HF patients (32) and is related to a poor prognosis, Additionally, anaemia can have clinical consequences such as fatigue or lethargy, depression, and impaired cognitive function which all might negatively affect quality of life (32)(33)(34).…”

Section: Factors Related To Quality Of Life and Symptoms Of Depressionmentioning

confidence: 99%

Quality of life and symptoms of depression in advanced heart failure patients and their partners

Jaarsma

Johansson

Ågren

et al. 2010

Current Opinion in Supportive &Amp; Palliative Care

View full text Add to dashboard Cite

2 Purpose of reviewTo provide an overview of factors related to quality of life and symptoms of depression in heart failure patients and their partners. Furthermore, to give an overview of interventions that can be effective in improving their quality of life and decrease depressive symptoms. Recent findingsQuality of life of patients with heart failure and their partners is poor compared to their age-matched peers from the general population and also compared to patients suffering from other chronic diseases. Furthermore, a considerable amount of heart failure patients is depressed. Depressive symptoms of patients and of their partners seemed to be interrelated, making interventions complicated but needed.Although the number of studies that specifically target improvement of quality of life and depression in heart failure patients and their partners is still small, several interventions are known to improve quality of life and these could be implemented in daily care. SummaryThis review considers demographic and clinical factor that are related to quality of life and depressive symptoms and addresses interventions that can contribute to improvement of quality of life of heart failure patients and their partners and decrease depressive symptoms.Education on self-care management and physical exercise are important to include in a disease management program. A multidisciplinary care approach including optimizing medical therapy and optimal symptom management is advised, focusing both on the patient and the caregiver. Treatment and care should not only focus on heart failure, but also address the consequences of co-morbidities and consequences of symptoms and therapies.

show abstract

Section: Factors Related To Quality Of Life and Symptoms Of Depressionmentioning

confidence: 99%

Quality of life and symptoms of depression in advanced heart failure patients and their partners

Jaarsma

Johansson

Ågren

et al. 2010

Current Opinion in Supportive &Amp; Palliative Care

View full text Add to dashboard Cite

show abstract

“…Indeed, the recently published CREATE and CHOIR studies revealed that overcorrection of anaemia with recombinant human EPO in patients with chronic kidney disease (CKD) was associated with increased cardiovascular events [18,19]. In Chronic Heart Failure (CHF) patients, appropriately powered phase-3 studies are lacking, although safety and feasibility studies have demonstrated promising beneficial effects without additional harm [20]. Nevertheless, treatment aimed at improving cardiac function in non-anaemic CHF patients at already elevated cardiovascular risk necessitates treatment strategies that exert the beneficial effects of EPO without increasing haematocrit levels.…”

Section: Introductionmentioning

confidence: 99%

Low‐dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit

Lipšic

Westenbrink

Meer

et al. 2008

European J of Heart Fail

View full text Add to dashboard Cite

Background: Erythropoietin (EPO) may improve cardiac function and induce neovascularisation in experimental models of chronic heart failure (CHF). However, the increased haematocrit associated with EPO treatment might exert concomitant deleterious effects. Aim: To investigate the haematocrit independent effects of EPO on cardiac function. Methods and results: Rats underwent permanent coronary artery ligation to induce myocardial infarction (MI) or sham surgery. Three weeks after MI, rats were randomly allocated to treatment with vehicle (MI) or the long-acting EPO analogue darbepoetin alfa administered in a high (40 μg/kg/3 weeks, MI-EPO-high) or a low-dose (0.4 μg/kg/3 weeks, MI-EPO-low). After 9 weeks, haemodynamic parameters, myocardial histology and Myosin Heavy Chain (MHC) isoforms were determined. High-dose EPO resulted in a significant increase in haematocrit (p b 0.01) while low-dose EPO had no effect on haematocrit levels. EPO significantly improved cardiac function in both EPO groups, reflected by increased left ventricular (LV)-developed pressure and improved contractility (dP/dt max ) and relaxation (dP/dt min ) indices of the LV at 9-weeks (all p b 0.05 compared to MI). The improved cardiac function was associated with increased capillary growth (38% in MI-EPO-high (p b 0.01) and 27% in MI-EPO-low (p b 0.05)) and an attenuated switch to slow β-MHC isoforms in both EPO groups. Conclusions: EPO improves cardiac function and induces neovascularisation at a dose that does not increase haematocrit, thereby circumventing the possible deleterious effects of increased erythropoiesis.

show abstract

“…The erythropoietic agent used in RED-HF (and TREAT) is different to the compounds used in CHOIR and CREATE. The largest difference is that darbepoetin alfa has a longer plasma half life, but it also has a stronger affinity for the erythropoietin receptor than the conventional compounds [15]. Although we have no indication that this will affect its adverse effect profile at the present time, this cannot be excluded.…”

Section: Summary and Implications Of Choir And Create For Red-hfmentioning

confidence: 80%

“…The patients in CREATE and CHOIR were fundamentally different to the target population of RED-HF [15,16]. This is critical, since these populations have different comorbidities, baseline renal function, aetiology of anaemia Table 1 Comparison of trials with erythropoietin CREATE CHOIR TREAT RED-HF n = 603 n = 1432 n = 4000 ⁎ n = 3400 ⁎ and concomitant medications (Table 1).…”

Section: Summary and Implications Of Choir And Create For Red-hfmentioning

confidence: 99%

“…This is critical, since these populations have different comorbidities, baseline renal function, aetiology of anaemia Table 1 Comparison of trials with erythropoietin CREATE CHOIR TREAT RED-HF n = 603 n = 1432 n = 4000 ⁎ n = 3400 ⁎ and concomitant medications (Table 1). Indeed, potential side effects of ESP therapy in CKD (discussed above) may not necessarily have the same untoward effects in CHF [15], but studies on this issue are needed. 2.…”

Section: Summary and Implications Of Choir And Create For Red-hfmentioning

confidence: 99%

See 1 more Smart Citation

Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial

Veldhuisen

McMurray

2007

European J of Heart Fail

View full text Add to dashboard Cite

Anemia in Chronic Heart Failure

Cited by 353 publications

References 107 publications

Quality of life and symptoms of depression in advanced heart failure patients and their partners

Quality of life and symptoms of depression in advanced heart failure patients and their partners

Low‐dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit

Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial

Contact Info

Product

Resources

About